Cogent Biosciences, Inc. is a high-risk biopharmaceutical company based in the United States. Specializing in precision therapies for genetically defined diseases, the company focuses on developing rational treatments to address the root cause of illnesses and enhance patient outcomes. One of their notable programs, CGT9486, is an ESG-approved selective tyrosine kinase inhibitor targeting the KIT D816V mutation, as well as other exon 17 mutations associated with serious conditions like Systemic Mastocytosis and gastrointestinal stromal tumors.